StockData
Scholar Rock Holding Corp logo

Scholar Rock Holding Corp (SRRK) company profile

SRRKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 2/30
$45.08+0.54 (+1.21%)

Close on Nov 17, 2026Market cap $5.49BP/E –Yield –

About Scholar Rock

Biological Products, (No Diagnostic Substances), SIC 2836

Scholar Rock is a biopharmaceutical company focused on discovering and developing therapies for spinal muscular atrophy and other rare neuromuscular conditions. Using a proprietary platform that targets latent growth factor precursors within tissue microenvironments, the company builds an anti-myostatin pipeline. Its lead product candidates include apitegromab, an investigational monoclonal antibody designed to inhibit myostatin activation in muscle, and SRK-439. The company develops treatments intended for pediatric and adult patients suffering from debilitating neuromuscular disorders.

The company operates with clinical development activities spanning the United States and Europe, supported by a customer-facing workforce of approximately fifty professionals in the United States and commercial readiness initiatives beginning in Germany. It aims to serve patient populations across a platform covering more than fifty countries globally. The provided text mentions scientific roots at Harvard Medical School and Boston Children’s Hospital, but it does not state the city or location of the company's corporate headquarters.

Summary of the business section of Scholar Rock's latest annual report, written by StockData.

Company profile

Company

Legal name
Scholar Rock Holding Corp
Headquarters
Cambridge, MA
Address
301 Binney Street, 3rd Floor 02142
Phone
(857) 259-3860
Employees
289, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, Boston, Massachusetts

Stock & identifiers

Ticker
SRRK
Exchange
Nasdaq
IPO date
May 24, 2018
Shares outstanding
122M, Aug 3, 2026
Public float
$2.60B, Jun 30, 2025
Filer category
Non-accelerated filer
SEC CIK
1727196
CUSIP
80706P103
ISIN
US80706P1030
FIGI
BBG00KT2RRM6
Share class FIGI
BBG00KT2RSD4
LEI
549300Z1FLPGL4OWJ459
EIN
82-3750435

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
David HallalChief Executive Officer, Director1,844,034
Akshay VaishnawPresident of R&D, Director630,542
Jay T. BackstromCHIEF EXECUTIVE OFFICER, Director425,561
Keith WoodsChief Operating Officer620,055
Vikas SinhaChief Financial Officer619,856
Mo QatananiCHIEF SCIENTIFIC OFFICER98,645
Jing L. MarantzCHIEF MEDICAL OFFICER126,012
Junlin HoGENERAL COUNSEL241,545
Caryn ParlavecchioCHRO169,087
Tracey SaccoChief Commercial Officer76,250
Erin MooreInterim PFO and PAO96,173
Edward H. MylesCOO & CFO111,345
Srinivas AkkarajuDirector7,131,508
Joshua ReedDirector20,466
Katie PengDirector34,322
Michael GilmanDirector59,554
Kristina BurowDirector2,460,368
Jeffrey S. FlierDirector27,871
Richard BrudnickDirector21,896

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025
David Hallal
$33.30M$44.34M$13.56M$487–
FY2025
Jay Backstrom
$17.49M$6.15M$13.56M$487–
FY2024$7.99M$35.21M$3.02M$478–
FY2023$4.11M$10.54M$2.16M$208–
FY2022
Jay Backstrom
$7.08M$7.18M$2.78M$36–
FY2022
Nagesh Mahanthappa
$2.84M$371.63K$2.78M$36–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsIncentive payOtherTotalvs. prior year
David Hallal
Chief Executive Officer and Chairman
$637.50K$2.00M$22.52M$7.62M$452.29K$67.65K$33.30M–
Akshay Vaishnaw, M.D., Ph.D.
President of R&D
$523.08K$2.00M$9.01M$3.05M$278.33K$32.56K$14.89M–
R. Keith Woods
Chief Operating Officer
$523.08K–$9.01M$3.05M$278.33K$57.19K$12.92M–
Vikas Sinha
Chief Financial Officer
$523.08K–$9.01M$3.05M$278.33K$14.04K$12.87M–
Jay Backstrom, M.D., M.P.H.
Former President and Chief Executive Officer
$600.23K–$5.90M$9.85M–$1.15M$17.49M+119%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
May 24, 2018
Offer price
$14.00
Securities offered
5,360,000
Gross proceeds
$75.04M
Exchange
Nasdaq
First trading day
May 24, 2018
First-day close
$15.50+10.7%
Lock-up ends (est.)
Nov 20, 2018

“The initial public offering price is $14.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of February 24, 2026, we had 289 full-time employees, of which 137 employees are engaged in research and development activities and 152 are engaged in general and administrative activities.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?